【ChiCTR-TTRCC-14004275】Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
ChiCTR-TTRCC-14004275
结束
/
/
/
2014-02-17
/
/
Sudden sensorineural hearing loss
Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
To evaluate the effects of Electroacupuncture (EA) and compare its therapeutic efficacy to Trancutaneous electrical nerve stimulation(TENS) and conventional medical therapy in cases of ISSHL
随机交叉对照
Ⅱ期
Block randomization
/
National Research Council of Thailand (NRCT)
/
40
/
2012-06-26
2014-01-31
/
1. Male or female, age > 18 to 80 years and legal age of consent; 2. Has diagnosis of first episode of unilateral sudden sensorineural hearing loss; 3. Audiogram shows sensorineural hearing loss > 30 dB at least 1 frequency of the affected ear, and if the subject is older than 50 years old; the hearing threshold of the contralateral ear must be 10 dB less the affected ear.；
请登录查看1. History of head injury, loud noise exposure, use of ototoxic drugs, infections of middle ears, brain infections; 2. History of coagulation defects or receive anticoagulants/ antiplatelets; 3. History of epilepsy, seizure, stroke, cerebral ischemia, or has cardiac pacemakers; 4. Immunocompromised status, including a debilitated state or Malignancy; 5. Physical examination and laboratory results reveal following findings: Vesicles at pinna, ear canal, or tympanic membrane/ Perforated tympanic membrane/ Fluid in middle ear space/ CNS abnormality/ Abnormal VDRL or TPHA/ Significant prolonged PT, PTT, INR; 6. MRI or CT scan shows structural abnormality of brain and auditory nerve; 7. Lack of ability or willingness to give informed consent.；
请登录查看National Research Council of Thailand (NRCT)
/
National Research Council of Thailand (NRCT)的其他临床试验
Faculty of Medicine, Chiang Mai University, Thailand的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04